These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35216677)

  • 21. Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
    Miyawaki T; Kenmotsu H; Mori K; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Harada H; Endo M; Ohde Y; Takahashi K; Takahashi T
    Clin Lung Cancer; 2020 Sep; 21(5):e405-e414. PubMed ID: 32205040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Memmott RM; Wolfe AR; Carbone DP; Williams TM
    J Thorac Oncol; 2021 Jul; 16(7):1086-1098. PubMed ID: 33845212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer.
    Ku BM; Kim Y; Lee KY; Kim SY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Eur J Immunol; 2021 Apr; 51(4):956-964. PubMed ID: 33506525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1/PD-L1 agents?
    Sternschuss M; Peled N; Allen AM; Dudnik E; Rotem O; Kurman N; Gal O; Reches H; Zer A
    Thorac Cancer; 2020 Aug; 11(8):2331-2334. PubMed ID: 32548905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
    Uruga H; Mino-Kenudson M
    Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testing New Neoadjuvant Combos in NSCLC.
    Cancer Discov; 2022 Jun; 12(6):1400-1401. PubMed ID: 35413108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm.
    Breimer LH; Nousios P; Olsson L; Brunnström H
    Scand J Clin Lab Invest; 2020 Sep; 80(5):360-369. PubMed ID: 32238062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.
    Jiang T; Liu H; Qiao M; Li X; Zhao C; Su C; Ren S; Zhou C
    Clin Lung Cancer; 2018 Mar; 19(2):e177-e184. PubMed ID: 29175386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
    Tsao MS; Le Teuff G; Shepherd FA; Landais C; Hainaut P; Filipits M; Pirker R; Le Chevalier T; Graziano S; Kratze R; Soria JC; Pignon JP; Seymour L; Brambilla E
    Ann Oncol; 2017 Apr; 28(4):882-889. PubMed ID: 28137741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression.
    Stinchcombe TE; Miksad RA; Gossai A; Griffith SD; Torres AZ
    Clin Lung Cancer; 2020 Sep; 21(5):389-394.e3. PubMed ID: 32409266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors.
    Tamminga M; de Wit S; Hiltermann TJN; Timens W; Schuuring E; Terstappen LWMM; Groen HJM
    J Immunother Cancer; 2019 Jul; 7(1):173. PubMed ID: 31291995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis.
    Tartarone A; Roviello G; Lerose R; Roudi R; Aieta M; Zoppoli P
    Future Oncol; 2019 Jul; 15(20):2423-2433. PubMed ID: 31237152
    [No Abstract]   [Full Text] [Related]  

  • 33. Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies.
    Shukuya T; Mori K; Amann JM; Bertino EM; Otterson GA; Shields PG; Morita S; Carbone DP
    J Thorac Oncol; 2016 Nov; 11(11):1927-1939. PubMed ID: 27496650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Atezolizumab in a first-line setting in non-small-cell lung cancer with high PD-L1 expression].
    Roulleaux Dugage M; Brosseau S
    Bull Cancer; 2021 Oct; 108(10):904-906. PubMed ID: 34598788
    [No Abstract]   [Full Text] [Related]  

  • 35. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.
    Peng DH; Rodriguez BL; Diao L; Gaudreau PO; Padhye A; Konen JM; Ochieng JK; Class CA; Fradette JJ; Gibson L; Chen L; Wang J; Byers LA; Gibbons DL
    Nat Commun; 2021 May; 12(1):2606. PubMed ID: 33972557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
    Tachihara M; Negoro S; Inoue T; Tamiya M; Akazawa Y; Uenami T; Urata Y; Hattori Y; Hata A; Katakami N; Yokota S
    BMC Cancer; 2018 Oct; 18(1):946. PubMed ID: 30285770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of PD-L1 status on survival outcomes in patients with stage II-III non-small cell lung cancer treated with chemotherapy.
    Karaca M; Tural D; Akar E; Unal D; Bayraktaoglu M; Akyurek N; Ozet A
    J BUON; 2020; 25(1):268-273. PubMed ID: 32277641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.
    Babacan NA; Pina IB; Signorelli D; Prelaj A; Garassino MC; Tanvetyanon T
    Clin Lung Cancer; 2020 Sep; 21(5):e456-e463. PubMed ID: 32265109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Research progress of immune checkpoint inhibitors in clinical diagnosis and treatment of non-small cell lung cancer].
    Huang Y; Xu K; Wang W; Cui F; Zeng Y; Hao ZX; Cai WP; He JX; Liu J
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):713-717. PubMed ID: 32988151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
    Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.